Crossmark

Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first

Crossref DOI link: https://doi.org/10.1007/s12094-018-1858-8

Published Online: 2018-03-28

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lim, C. https://orcid.org/0000-0001-9644-2572
Doussot, A.

Osseis, M.

Esposito, F.

Salloum, C.

Calderaro, J.

Tournigand, C.

Azoulay, D.
License Information

Text and Data Mining valid from 2018-03-28
More Information

Article History

Received: 27 December 2017

Accepted: 6 March 2018

First Online: 28 March 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: This study has been approved by the Hospital ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: Informed consent was obtained from all individual patients included in the study.